Adding Cabometyx to Immunotherapy Combination Improves Outcomes for Advanced Kidney Cancer
September 12th 2022The addition of Cabometyx to the current standard-of-care frontline regimen of Opdivo plus Yervoy improved progression-free survival outcomes in patients with advanced kidney cancer.
Read More
Adding the Novel Drug Oleclumab to Imfinzi and Chemotherapy Fails to Improve TNBC Outcomes
September 9th 2022Adding the novel drug oleclumab to Imfinzi and chemotherapy for the frontline treatment of advanced triple-negative breast cancer did not improve clinical outcomes, according to recent study findings.
Read More